Cover Image: May 2006 Scientific American Magazine See Inside

Shutting Down Alzheimer's [Preview]

New research reveals strategies for blocking the molecular processes that lead to this memory-destroying disease















Share on Tumblr

ALZHEIMER'S DISEASE

ALZHEIMER'S DISEASE gradually severs even one's oldest memories, but scientists are working on promising treatments. Some therapies could clamp the molecular cutting that appears to initiate the disorder; others could prevent the harmful effects that follow. Image: TINA WEST

More In This Article

The human brain is a remarkably complex organic computer, taking in a wide variety of sensory experiences, processing and storing this information, and recalling and integrating selected bits at the right moments. The destruction caused by Alzheimer's disease has been likened to the erasure of a hard drive, beginning with the most recent files and working backward. An initial sign of the disease is often the failure to recall events of the past few days--a phone conversation with a friend, a repairman's visit to the house--while recollections from long ago remain intact. As the illness progresses, however, the old as well as the new memories gradually disappear until even loved ones are no longer recognized. The fear of Alzheimer's stems not so much from anticipated physical pain and suffering but rather from the inexorable loss of a lifetime of memories that make up a person's very identity.

Unfortunately, the computer analogy breaks down: one cannot simply reboot the human brain and reload the files and programs. The problem is that Alzheimer's does not only erase information; it destroys the very hardware of the brain, which is composed of more than 100 billion nerve cells (neurons), with 100 trillion connections among them. Most current medications for Alzheimer's take advantage of the fact that many of the neurons lost to the disease release a type of chemical communicator (or neurotransmitter) called acetylcholine. Because these medicines block an enzyme responsible for the normal decomposition of acetylcholine, they increase the levels of this otherwise depleted neurotransmitter. The result is stimulation of neurons and clearer thinking, but these drugs typically become ineffective within six months to a year because they cannot stop the relentless devastation of neurons. Another medication, called memantine, appears to slow the cognitive decline in patients with moderate to severe Alzheimer's by blocking excessive activity of a different neurotransmitter (glutamate), but investigators have not yet determined whether the drug's effects last more than a year.


Subscribe     Buy This Issue

Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.

Comments

Add Comment
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Shutting Down Alzheimer's: Scientific American Magazine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X